Feature | May 15, 2014

Linking Vascular Inflammation to Obesity, Atherosclerosis


May 15, 2014 — A clinical study in The Journal of Experimental Medicine shows that I?B kinase ? (IKK?) functions in smooth muscle cells to regulate vascular inflammatory responses and atherosclerosis development.

Inflammatory responses are the driving force of atherosclerosis, a process that involves the hardening and thickening of artery walls due to excess fatty deposits. IKK? is a central coordinator of inflammatory responses that has been implicated in vascular diseases, but its role in atherosclerosis has been unclear.

Now, Changcheng Zhou and colleagues from the University of Kentucky show that deficiency of IKK? in smooth muscle cells decreases vascular inflammation and atherosclerosis development in mice. Surprisingly, the lack of IKK? also blocks the differentiation of fat cells and causes an accumulation of body fat precursor cells, thus protecting the animals from diet-induced obesity. These novel findings suggest that the kinase acts as a regulator of fat cell differentiation. The use of IKK? inhibitors may therefore provide an innovative treatment for atherosclerosis, obesity, and metabolic disorders.

Sui, Y., et al. 2014. J. Exp. Med.doi:10.1084/jem.20131281

For more information: www.jem.org


Related Content

News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
Subscribe Now